NEW YORK (GenomeWeb News) – Mitochondrial DNA-based test developer Mitomics today announced a realignment of its product development operations, resulting in the elimination of eight jobs.
Chief Laboratory Officer Jennifer Creed will also now lead end-to-end product development for the company based in Thunder Bay, Ontario.
In a statement, Mitomics President and CEO Robert Poulter said that the firm "continues to face tremendous opportunity and potential for growth in the diagnostics arena."
The company's lead product is its Prostate Core Mitomic Test, or PCMT, launched in 2011 and conducted out of its CLIA-certified laboratory. Using existing biopsy tissue, the test identifies biomarkers that are associated with malignant cells in benign tissue. The firm is also developing tests for detecting breast cancer, bladder cancer, thyroid cancer, melanoma, ovarian cancer, pancreatic cancer, uterine cancer, and endometriosis, it said.